COVID-19 antibody research coming out of the University of Texas stars an unlikely participant: A llama named Winter. University of Texas at Austin/Facebook

In the race to find a treatment for the novel coronavirus, researchers at the University of Texas at Austin have announced a potential breakthrough — thanks to a llama.

Scientists from Texas' flagship university who have been collaborating with the National Institutes of Health and Ghent University in Belgium identified an antibody treatment that could potentially neutralize the virus that causes COVID-19.

The researchers detail their work in the May 5 edition of Cell, a scientific journal.

"This is one of the first antibodies known to neutralize SARS-CoV-2," said Jason McLellan, associate professor of molecular biosciences at UT Austin and co-senior author of the paper, in a release. (FYI, SARS-CoV-2 is referring to the virus that causes COVID-19.)

Using a Belgian llama named Winter, scientists were able to identify two antibodies the animal produces when it comes into contact with a foreign body (such as the coronavirus). The first is similar to a human antibody and the second is much smaller, about one-quarter of the size of the other.

This is Winter. Photo courtesy of University of Texas at Austin

Researchers were able to link two copies of this special llama antibody to create a new antibody. This new antibody binds tightly to a key protein on the coronavirus germ that causes COVID-19 and could possible be nebulized and put into an inhaler.

"That makes them potentially really interesting as a drug for a respiratory pathogen because you're delivering it right to the site of infection," said Daniel Wrapp, a UT graduate student in McLellan's lab and co-first author of the paper.

Unlike vaccines, which can take up to two months to take effect, antibody treatment can be used in more vulnerable populations as a way to fight off the virus.

"Vaccines have to be given a month or two before infection to provide protection," McLellan said. "With antibody therapies, you're directly giving somebody the protective antibodies and so, immediately after treatment, they should be protected. The antibodies could also be used to treat somebody who is already sick to lessen the severity of the disease."

From here, research turns to preclinical studies, using hamsters and primates for testing. If successful, they will move onto humans.

If you're wondering just how a group of researchers living in different parts of the globe were able to make this discovery seemingly overnight, that's because they've actually been working on it since 2016, when Winter was just 9 months old.

The experiment began as a way to develop vaccinations for two earlier versions of the coronavirus: SARS-CoV-1 and MERS-CoV. Their years of research allowed the scientists to pivot in recent months to isolating the protein in COVID-19.

As for Winter, she's now 4 years old and still lives with about 130 llamas on a farm in Belgium, likely unaware of her contribution to potentially altering the course of COVID-19 forever.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

Houston investment firm names tech exec as new partner

new hire

Houston tech executive Robert Kester has joined Houston-based Veriten, an energy-focused research, investment and strategy firm, as technology and innovation partner.

Kester most recently served as chief technology officer for emissions solutions at Honeywell Process Solutions, where he worked for five years. Honeywell International acquired Houston-based oil and gas technology company Rebellion Photonics, where Kester was co-founder and CEO, in 2019.

Honeywell Process Solutions shares offices in Houston with the global headquarters of Honeywell Performance Materials and Technologies. Honeywell, a Fortune 100 conglomerate, employs more than 850 people in Houston.

“We are thrilled to welcome Robert to the Veriten team,” founder and CEO Maynard Holt said in a statement, “and are confident that his technical expertise and skills will make a big contribution to Veriten’s partner and investor community. He will [oversee] every aspect of what we do, with the use case for AI in energy high on the 2025 priority list.”

Kester earned a doctoral degree in bioengineering from Rice University, a master’s degree in optical sciences from the University of Arizona and a bachelor’s degree in laser optical engineering technology from the Oregon Institute of Technology. He holds 25 patents and has more than 25 patents pending.

Veriten celebrated its third anniversary on January 10, the day that the hiring of Kester was announced. The startup launched with seven employees.

“With the addition of Dr. Kester, we are a 26-person team and are as enthusiastic as ever about improving the energy dialogue and researching the future paths for energy,” Holt added.

Kester spoke on the Houston Innovators Podcast in 2021. Listen here

.